<DOC>
	<DOCNO>NCT00749216</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) multiple dose Solanezumab subject mild-to-moderate AD Japanese population .</brief_summary>
	<brief_title>Solanezumab Safety Study Japanese Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Men nonfertile woman , least 50 year age . ( Women surgically sterilize must postmenopausal least 1 year . ) Patients mild moderate AD follow disease diagnostic criterion National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criterion Modified Hachinski Ischemia Scale score ≦ 4 Folstein MiniMental State Examination ( MMSE ) score 15 26 Geriatric Depression Scale ( GDS ) score ≦ 10 staffadministered short form Patients n't reliable caregiver frequent contact patient , accompany patient office and/or available telephone designate time , monitor administration prescribe medication . Patients MRI CT scan since onset symptom AD inconsistent diagnosis AD . Patients receive acetylcholinesterase inhibitor ( AChEIs ) memantine le 4 month , less 2 month stable therapy treatment . Patients current serious unstable illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic ( AD ) , psychiatric , immunologic , hematologic disease condition , investigator subinvestigator ( ) 's opinion , could interfere analysis safety efficacy study . Patients history within last 5 year serious infectious disease affect brain ( include neurosyphilis , meningitis , encephalitis ) head trauma result protracted loss consciousness within last 5 year , multiple episode head trauma . Patients history within last 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal PSA postresection . Patients allergy humanize monoclonal antibody . Patients history within last 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal PSA postresection . Patients ECG abnormality obtain , opinion investigator , clinically significant regard subject 's participation study , include QTc prolongation ( Bazett 's correct QTc interval , QTcB ; male &gt; 435 msec female &gt; 455 msec ) abnormally wide QRS complex ( result bundlebranch block , interventricular conduction delay , pacemaker ) . Patients current , require use expect use exclude drug duration ( These drug include typical neuroleptic ( antipsychotic ) . In addition , typical neuroleptic may take within 4 week . Patients currently take chronic medication affect central nervous system ( CNS ) function , dosestabilized least 4 week . Patients ventriculoperitoneal shunt gamma globulin ( IgG ) therapy within last year . Patients previously complete withdrawn study previous participation study investigate active immunization Aβ . Patients contraindication MRI study , include claustrophobia , presence metal ( ferromagnetic ) implant , cardiac pacemaker . Patients weigh less 40 kg .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>